van Rooijen & Partners is proud to inform: <<
Press release.
Inamed acquires patent for inhalation of aspirin to treat virus infection
Gemuenden, Sep. 16, 2005. Germany based Inamed - Intelligent Aerosol Medicine today announced the acquisition of exclusive rights for inhaled Aspirin to block the propagation of influenza viruses in the lung. The technology has been developed and patented by a team of German scientists. The licence agreement gives Inamed the possibility to market the patent worldwide and also to bring in Inamed?s technology for precise and targeted drug delivery to the lung.
Dr. Gerhard Scheuch, founder and CEO of Inamed: "We are very happy about this acquisition, since we see the immense medical need for a better influenza therapy. We are looking forward to a further fruitful cooperation with this excellent research team."
Talks to possible investors and marketing partners have already been started, while the concrete partnering strategy is still open. Scheuch: "We will decide in a short time frame whether to bring this project to a further level by ourselves or make this a licensing business. Several options are possible and the next steps depend on the feedback from our negotiations."
Combining the drug with Inamed's delivery technology can increase the market chances for Aspirin considerably. As shown in other projects, controlled inhalation helps to reduce dose variability and so leverages success probability within clinical projects.
About Aspirin inhalation
German researchers Stephan Ludwig (Muenster), Stephan Pleschka (Giessen) and Oliver Planz, (Tuebingen) focused their research on influenza virus induced cellular signaling and found that especially IKK and NF-kB are required for efficient influenza virus reproduction. Their work showed that Aspirin can inhibit these important replication mechanisms, while being not toxic and not producing resistant virus variants.
About Inamed
Inamed GmbH - Intelligent Aerosol Medicine is a Germany-based drug delivery company, specializing in highly efficient aerosol technology and inhalation systems.
As a leading service provider for in-vitro and in-vivo inhalation studies, Inamed partners globally with leading pharmaceutical and biotechnology companies to apply their inhalation platforms to pharmaceuticals that require critical dosage control. Inamed is privately held and has facilities in Munich (R&D) and Gemuenden/Wohra (Headquarters and Logistics).
Contact
Axel Fischer, Inamed GmbH, Intelligent Aerosol Medicine, Wohraer Str. 37, D-35285 Gemuenden, Germany, Tel. +49 (0)6453 64818-0, Fax +49 (0)6453 64818-22, e-mail, web
Stephan Ludwig, Institute of Molecular Virology, Center for Molecular Biology of Inflammation (ZMBE), Von-Esmarch-Str. 56, D-48149 Muenster, Germany, Tel. +49 251 835 7791, Fax. +49 251 835 7793, e-mail, web